Venetoclax
Spezifikationen
1257044-40-8CAS-Nummer
820-130-9EG-Nummer
4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamideIUPAC-Name
C45H50ClN7O7SChemische Formel
868.4 g/molMolekulargewicht
Venetoclax; 1257044-40-8; ABT-199; Venclexta; GDC-0199; ABT199; venclyxto; ABT 199; RG7601; GDC 0199; RG-7601; 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; N54AIC43PW; Benzamide, 4-[4-[[2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-; CHEBI:133021; DTXSID30154863; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-n-({3-nitro-4-[(tetrahydro-2h-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; benzamide, 4-(4-((2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl)methyl)-1-piperazinyl)-n-((3-nitro-4-(((tetrahydro-2h-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-2-(1h-pyrrolo(2,3-b)pyridin-5-yloxy)-; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-(3-nitro-4-{[(oxan-4-yl)methyl]amino}benzenesulfonyl)-2-{1H-pyrrolo[2,3-b]pyridin-5-yloxy}benzamide; 4-{4-[(4'-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1'-biphenyl]]-2-yl)methyl]piperazin-1-yl}-N-(3-nitro-4-{[(oxan-4-yl)methyl]amino}benzene-1-sulfonyl)-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide; venetoclaxum; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-(3-nitro-4-(((oxan-4-yl)methyl)amino)benzenesulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl)methyl)piperazin-1-yl)-N-(3-nitro-4-(oxan-4-ylmethylamino)phenyl)sulfonyl-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide; 4-(4-((4'-chloro-5,5-dimethyl(3,4,5,6-tetrahydro(1,1'-biphenyl))-2-yl)methyl)piperazin-1-yl)-N-(3-nitro-4-(((oxan-4-yl)methyl)amino)benzene-1-sulfonyl)-2-((1H-pyrrolo(2,3-b)pyridin-5-yl)oxy)benzamide; RefChem:58112; DTXCID0077354; L01XX52; ABT-0199; Venetoclax (ABT-199); Venetoclax (ABT199); UNII-N54AIC43PW; C45H50ClN7O7S; MFCD23160052; Venetoclax; Abt-199; ABT 199 (Venetoclax); 4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-benzamide; ABT-199 (GDC-0199); 2-((1H-Pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide; 2-(1H-Pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methy; BDBM189459; ABT 199 (>99%)(Venetoclax); 4-[4-[[2-(4-chlorophenyl)-4,4-dimethyl-cyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(tetrahydropyran-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; Venetoclax [USAN:INN]; Venclexta (TN); ABBVIE; Venetoclax (Standard); VENETOCLAX [MI]; Venetoclax(ABT-199); VENETOCLAX [INN]; VENETOCLAX [JAN]; VENETOCLAX [USAN]; Venetoclax(ABT-199)?; VENETOCLAX [WHO-DD]; MLS006010298; SCHEMBL523816; Venetoclax (JAN/USAN/INN); GTPL8318; orb1226663; orb1306442; orb3141366; CHEMBL3137309; SCHEMBL19236295; SCHEMBL29353714; SCHEMBL29360081; SCHEMBL29390802; SCHEMBL29801595; VENETOCLAX [ORANGE BOOK]; BDBM60828; EX-A168; GLXC-06797; HMS3653J06; HMS3745E07; HMS5086M05; BDBM50162774; EBC-17182; HY-15531R; NSC766270; AKOS025289539; CCG-270543; CS-1155; DB11581; FV63222; KS-1470; NSC-766270; SB16499; NCGC00345789-01; NCGC00345789-03; NCGC00345789-04; NCGC00345789-05; NCGC00345789-10; NCGC00345789-11; NCGC00345789-12; 4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; AC-28754; BP-43649; DA-35360; HY-15531; SMR004701366; SY048011; CHRONIC LYMPHOCYTIC LEUKAEMIA THERAPY; NS00073446; SW219672-1; T2119; D10679; US9174982, 5; EN300-7399830; US9174982, 369; BRD-K62391742-001-03-0; BRD-K62391742-001-08-9; BRD-K62391742-001-09-7; Q23671272; Z2037279542; )methyl]amino}phenyl)sulfonyl]-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide; 2-[[Pyrrolo[2,3-b]pyridin-5-yl]oxy]-4-[4-[[4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-2-biphenylyl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(4-tetrahydropyranyl)methyl]amino]phenyl]sulfonyl]benzamide; 4-(4-((2-(4-CHLOROPHENYL)-4,4-DIMETHYLCYCLOHEX-1-EN-1-YL)METHYL)PIPERAZIN-1-YL)-N-((3-NITRO-4-((TETRAHYDRO-2HPYRAN-4-YLMETHYL) AMINO)PHENYL)SULFONYL)-2-(1H-PYRROLO(2,3-B)PYRIDIN-5-YLOXY)BENZAMIDE; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(oxan-4-ylmethyl)amino]benzene}sulfonyl)-2-{1H-pyrrolo[2,3-b]pyridin-5-yloxy}benzamide; 4-{4-[(4'-Chloro-5,5-dimethyl-3,4,5,6-tetrahydro[1,1'-biphenyl]-2-yl)methyl]piperazin-1-yl}-N-(3-nitro-4-{[(oxan-4-yl)methyl]amino}benzene-1-sulfonyl)-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide; 4-{4-[(4'-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1'-biphenyl]]-2-yl)methyl]piperazin-1-yl}-N-[(3-nitro-4-{[(oxan-4-yl; 4-{4-[(4'-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1'-biphenyl]]-2-yl)methyl]piperazin-1-yl}-N-[(3-nitro-4-{[(oxan-4-yl)methyl]amino}phenyl)sulfonyl]-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide; ABT-199; 2-(1H-Pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methy; VENETOCLAXVENCLEXTAABT-199A-12314-[4-[[2-(4-CHLOROPHENYL)-4,4-DIMETHYLCYCLOHEX-1-EN-1-YL]METHYL]PIPERAZIN-1-YL]-N-[[3-NITRO-4-[[(TETRAHYDRO-2H-PYRAN-4-YL)METHYL]AMINO]PHENYL]SULFONYL]-2-[(1H-PYRROLO[2,3-B]PYRIDIN-5-YL)OXY]BENZAMIDESynonyme
Produkte, die Venetoclax enthalten
벤클렉스타정50밀리그램(베네토클락스)벤클렉스타정10밀리그램(베네토클락스)벤클렉스타정100밀리그램(베네토클락스)VENCLYXTO 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULAVENCLYXTO 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULAVENCLYXTO 10 MG COMPRIMIDOS RECUBIERTOS CON PELICULAVENCLYXTO 50 MG COMPRIMIDOS RECUBIERTOS CON PELICULAVENCLYXTO 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULAVENCLYXTO 50 mg, comprimé pelliculéVENCLYXTO 100 mg, comprimé pelliculéVENCLYXTO 10 mg, comprimé pelliculéVenetoclax - Changzhou Pharmaceutical Factory
Seite 1 von 4
Unternehmen, die Venetoclax verkaufen
MP
Macleods Pharmaceuticals LimitedIndiaAD
Abbvie Deutschland GmbH & Co. KGGermanyDR
Dr. Reddy's LaboratoriesIndiaML
MSN LaboratoriesIndiaSI
Sinoway Industrial Co.Ltd.ChinaSeite 1 von 3